In what appears to be a case of first impression, on August 23, 2021 U.S. District Judge John Z. Lee of the United States District Court for the Northern District of Illinois denied a biosimilar applicant's motion to dismiss a patent infringement suit brought under the Biosimilar Price Competition and Innovation Act ("BPCIA") against a foreign parent corporation that did not file or sign the relevant abbreviated Biologics License Application ("aBLA"). AbbVie Inc. v. Alvotech hf., No. 21-cv-02258, (N.D. Ill.). In so doing, Judge Lee relied heavily on parallels between the Hatch-Waxman Act and the BPCIA. Plaintiffs, AbbVie Inc. and AbbVie Biotechnology Ltd. (collectively, "AbbVie"), make the biologic, Humira ® (adalimumab), which is used to treat a variety of autoimmune conditions including rheumatoid arthritis, psoriasis, and Crohn's disease.